Fig. 2.
Reduced expression of CD38 following celecoxib treatment. Changes in CD38 density (molecules/cell) in celecoxib (COX-2i)-treated and control groups from weeks 0 to 12 are shown for different T cell subsets, including total CD8+ and CD8+ PD-1+ T cells (top panels) and the PD-1-positive subsets of CCR7+ CD27+ and CCR7− CD27− memory CD8+ T cells (bottom panels). Median values and interquartile ranges (25th to 75th percentiles) are indicated. P values of <0.10 are shown in the relevant panels (Wilcoxon matched-pair test). Groupwise differences between the COX-2i-treated and control groups at week 12 were assessed by MWU and are indicated by asterisks. n.s., not significant.